THE SHORT ANSWER
High-Performance Science Teams™ helps clinical CROs run each study as one team: project management, clinical monitoring, site start-up, data management, biostatistics, medical monitoring, and BD. It targets the behaviors that erode sponsor trust after award: timelines promised in the bid defense that delivery never validated, risk reported late, change orders that become disputes, and sponsors hearing different stories from different functions.
Why do sponsors lose confidence in a clinical CRO?
The bid defense goes well. The team in the room is sharp, the enrollment plan is credible, the start-up timeline is aggressive but defensible. Six months later, site activation is behind, the sponsor’s clinical lead is escalating to your executive sponsor, and the joint operating committee has become a weekly status interrogation.
The science of running the trial rarely fails. What fails is the team behind it: the handoff from proposal to delivery, the way risk moves from a CRA’s visit report to the sponsor’s inbox, and whether project management, monitoring, data management, and biostatistics give the sponsor one answer or four.
What does a slipped day cost your sponsor?
Your sponsors know the number. Tufts Center for the Study of Drug Development puts the mean direct cost of running a Phase II or III trial at roughly $40,000 per day, about $23,700 for Phase II and $55,700 for Phase III (Tufts CSDD, 2024). Every day a CRO team loses to an internal handoff is a day the sponsor pays for.
Protocol amendments magnify it, and the CRO executes most of them. Tufts CSDD’s latest benchmark 950 protocols from 16 pharma companies and CROs, published in 2024 found 76% of protocols now have at least one amendment, averaging 3.3 each. Implementing one takes an average of 260 days from identifying the need to final oversight approval, and investigative sites operate on different protocol versions for an average of 215 days. Most amendments are now judged unavoidable. How fast and cleanly the CRO team implements them is not.
What does team dysfunction look like inside a clinical CRO?
- The bid-to-delivery gap. Proposals and BD commit to a site activation curve and enrollment plan the delivery team never pressure-tested, and the project manager inherits a timeline to rebaseline in month three.
- Green until it’s red. Risk sits in CRA visit reports, site feasibility notes, and query aging reports long before it reaches the sponsor, because no one wants to be the function that raised it.
- The project manager as switchboard. Every decision routes through the PM, who has accountability for the study but no authority over monitoring, data management, or biostatistics resources.
- Change orders as conflict. Out-of-scope work is absorbed to keep the sponsor happy, then surfaces months later as a change order the sponsor sees as a surprise.
- Amendment rollout without an owner. Regulatory, start-up, monitoring, and data management each implement their piece of an amendment on their own clock, and sites run mixed protocol versions longer than they should.
- Four voices to the sponsor. The PM, the clinical team lead, the data manager, and the medical monitor each describe study status differently in the same governance meeting.
Why don’t new CTMS platforms, reorganizations, or more PMs fix it?
Clinical CROs reach for vertical fixes when delivery slips: a new CTMS or risk-based monitoring platform, a shift between full-service and functional service models, a regional reorganization, more project managers. The dashboard gets better. The handoffs don’t.
Adding project managers to a team without clear decision rights adds switchboards, not speed. And sponsors who switch CROs discover that the new provider’s delivery team has the same habits. The problem is horizontal how functions work together on one study and it needs a horizontal fix.
How does High-Performance Science Teams™ work for clinical CRO teams?
The program applies Guttman Development Strategies’ horizontal high-performance team model to CRO delivery leadership and cross-functional study teams, working on live studies and live sponsor relationships. Where it helps, sponsor counterparts can be included so governance runs as one team.
| Sponsor-trust pattern | Root behavior | What HPT installs |
| Timelines rebaselined after award | BD and delivery goals misaligned | A bid-to-delivery protocol: delivery leads validate start-up and enrollment assumptions before the bid defense |
| Risk reported late | Low candor across functions | An early-warning protocol: study risks raised within a set window, without blame |
| PM bottleneck | Accountability without authority | Explicit decision rights across PM, clinical team lead, data management, and biostatistics |
| Change-order disputes | Avoiding hard sponsor conversations | Shared norms for flagging scope change at the moment it occurs |
| Slow amendment rollout | No cross-functional owner | Peer accountability for amendment implementation across regulatory, start-up, monitoring, and data management |
| Mixed messages in governance | No single internal position | An align-before-you-speak rule so the sponsor hears one study status |
How does this connect to the CRO’s customer-facing roles?
High-Performance Science Teams™ aligns the delivery team. Bench to Business™, our companion program, coaches the people who carry the sponsor relationship — project managers, clinical team leads, CRAs moving into lead roles, and BD scientists to communicate data, negotiate scope, and deliver difficult news with confidence. CROs that run both close the gap between what the bid defense promised and what the study delivers.
What is outside the scope of the program?
High-Performance Science Teams™ doesn’t replace feasibility analytics, patient-recruitment vendors, or your quality management system. It makes the team that uses them faster, more candid, and more consistent with the sponsor.
Who is it for?
CRO presidents and COOs, VPs of Clinical Operations and Project Delivery, project directors, heads of BD and proposals, and CHROs at full-service, specialty, and therapeutic-area-focused clinical CROs — especially those scaling delivery teams, integrating acquisitions, or working to become a preferred provider for key sponsors.
How do we get started?
Start with the Science Team 360™ — a short, confidential team-level diagnostic that shows exactly where decision rights, alignment, and accountability are breaking down inside your CRO delivery team. You get a readout before anyone commits to a full engagement.
Request a Science Team 360™ conversation at bench2business.bio.
Frequently asked questions
Why do sponsors switch clinical CROs?
Sponsors most often lose confidence over delivery experience rather than scientific capability: timelines rebaselined soon after award, risks reported late, change orders that arrive as surprises, and inconsistent status reporting across the CRO team.
How long does a protocol amendment take to implement?
According to Tufts CSDD’s 2024 benchmark of 950 protocols, the average time from identifying the need to amend to last oversight approval is 260 days, and sites operate on different protocol versions for an average of 215 days.
How can a clinical CRO improve the sponsor relationship?
By aligning BD, project management, monitoring, data management, and biostatistics on shared commitments to each study — validating timelines before the bid defense, raising risk early, flagging scope changes when they occur, and presenting one study status to the sponsor.
Does High-Performance Science Teams™ replace CTMS or risk-based monitoring?
No. CTMS and risk-based monitoring surface risk and status. High-Performance Science Teams™ improves how the CRO team acts on that information and communicates it to the sponsor.
How do we start?
With the Science Team 360™, a confidential diagnostic that shows where alignment, decision rights, and accountability break down in your study delivery teams.
Sources
- Tufts CSDD, “How Much Does a Day of Delay in a Clinical Trial Really Cost?” White paper, August 2024 — https://csdd.tufts.edu/publications/articles
- Getz K., Smith Z., Botto E., Murphy E., Dauchy A. “New Benchmarks on Protocol Amendment Practices, Trends and their Impact on Clinical Trial Performance.” Therapeutic Innovation & Regulatory Science 58:539–548 (2024) — https://doi.org/10.1007/s43441-024-00622-9
- Guttman, H.M. Great Business Teams: Cracking the Code for Standout Performance (Wiley, 2008) — https://www.guttmandev.com/great-business-teams
Figures from third-party studies are cited as published. Cross-industry data is presented as directional for life science. Program outcomes described are targets teams track against their own Science Team 360™ baseline, not guaranteed results.